Bipolar Disorder (2018) |
1.88 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZC3HC1 |
Bipolar Disorder or Schizophrenia |
1.96 |
7 |
4 |
8.9 |
-0.46 |
2.5e-01 |
CERS5 CHMP1A FAM57B FES FURIN NT5C2 TBC1D19 |
Depressed Affect (Nagel 2018) |
1.25 |
5 |
3 |
6.7 |
-0.51 |
3.8e-01 |
ACP2 OSGIN2 RP5-1115A15.1 SH2B3 WNT3 |
Depression (Nagel 2018) |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP5-1115A15.1 |
Intelligence (Savage-Jansen 2018) |
1.21 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
DCAF16 GTF2B RBL2 |
Neuroticism (Nagel 2018) |
1.16 |
5 |
2 |
4.4 |
-0.41 |
4.9e-01 |
ACP2 FURIN KAT8 RP5-1115A15.1 WNT3 |
Schizophrenia (2018) |
1.81 |
4 |
3 |
6.7 |
-0.78 |
1.2e-01 |
FAM57B FES FURIN NT5C2 |
Worry (Nagel 2018) |
1.27 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
KAT8 NT5C2 |
Alzheimer’s Disease (including proxy) |
1.44 |
4 |
2 |
4.4 |
-0.99 |
7.4e-03 |
ACE KAT8 PRKD3 PVRIG |
Crohns Disease (2017) |
1.41 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
NTN5 PDLIM4 PMS2P5 |
Irritable Bowel Disease (IBD) |
1.50 |
5 |
1 |
2.2 |
-0.82 |
8.9e-02 |
GMEB2 OPRL1 PDLIM4 PMS2P5 RGS19 |
Ulcerative Colitis (UC) |
1.48 |
2 |
0 |
0.0 |
-0.29 |
6.4e-01 |
OPRL1 RGS19 |
Major Depression (MDD) |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Reaction Time |
1.12 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SH2B3 |
Verbal and Numeric Reasoning (VNR) |
1.15 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
DCAF16 RBL2 TEX15 |
Breast Cancer |
2.25 |
12 |
3 |
6.7 |
0.50 |
5.9e-02 |
CSK FES FURIN LSP1 OPRL1 PDLIM4 PMS2P5 RGS19 RP11-1055B8.4 SIK2 SLC4A7 UBL7 |
Ovarian Cancer |
1.27 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO WNT3 |
Prostate Cancer |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TNNT3 |
Body Mass Index (BMI) (2010) |
1.77 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
STAG3L1 |
Coronary Artery Disease (CAD) |
2.07 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ABO MRAS |
Crohns Disease (2012) |
1.25 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PDLIM4 |
Fasting Glucose |
1.63 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACP2 |
HDL Cholesterol |
1.44 |
4 |
1 |
2.2 |
-0.70 |
3.0e-01 |
ACP2 ADRB1 CTSW PIGV |
LDL Cholesterol |
1.81 |
4 |
1 |
2.2 |
-0.28 |
7.2e-01 |
ABO NTN5 PIGV SH2B3 |
Neuroticism (2016) |
1.25 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
MSRA NEIL2 |
Primary Biliary Cirrhosis |
1.23 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CISD2 SH2B3 |
Rheumatoid Arthritis |
1.31 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RGS19 SH2B3 |
Schizophrenia (2014) |
1.78 |
6 |
3 |
6.7 |
-0.36 |
4.3e-01 |
CERS5 FAM57B FES FURIN NT5C2 RP5-1115A15.1 |
Triglycerides |
1.45 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
KAT8 NEIL2 NRBF2 |
Blood Eosinophil Count |
3.57 |
23 |
17 |
37.8 |
0.59 |
2.9e-03 |
ABO ADRB2 CCDC36 CERS5 FAM57B FBF1 KAT8 NDUFAF6 NUCB2 PDLIM4 PDXK PIGV RP11-617D20.1 RP5-1115A15.1 SH2B3 SIK2 SIPA1 TCHP TSPY26P WNT3 ZC3HC1 ZNF652 ZNF831 |
Blood Platelet Count |
2.91 |
43 |
34 |
75.6 |
-0.25 |
8.7e-02 |
ABCF3 AC091133.1 C20orf160 CAPZA1 CAST CERS5 CLCN6 COX5A CSK CTSW CWF19L2 DCAF16 FBF1 GMEB2 GTF2B HDAC7 HEXIM1 LFNG MGRN1 MPI MTHFR MYO9B NELFCD NRBF2 NTN5 NUCB2 PDLIM4 PHIP PIGV RHOC RP11-617D20.1 RPP25 SH2B3 SIK2 SLC4A7 SWAP70 TH1L TMEM170A TUBB1 UBL7 USP37 ZC3HC1 ZNF318 |
Blood Red Count |
1.91 |
44 |
26 |
57.8 |
0.24 |
8.8e-02 |
ABO ARID3B BICC1 C20orf160 C4orf22 CENPW CHMP1A CLCN6 COX5A CSK CYB5D1 FAM57B FBF1 GMEB2 GTF2B HEXIM1 INPP5A IPO11 KAT8 MGRN1 MPI MTHFR NCOA1 NDUFAF6 NELFCD NPPA NPPA-AS1 NT5C2 PDXK PVRIG RP11-617D20.1 RPP25 SH2B3 SLC35F6 TDRD1 TH1L TSPY26P TUBB1 UBL7 ULK3 USP37 VEGFB WNT3 ZNF641 |
Blood White Count |
1.93 |
30 |
14 |
31.1 |
0.57 |
7.3e-04 |
ABO ADRB2 C10orf118 CERS5 CMIP CYB5D1 DCAF16 FBF1 FES FLJ12825 FURIN GTF2B KB-1107E3.1 KCNK3 MGRN1 MOBP NRBF2 NT5C2 PDLIM4 PLCB1 RP11-617D20.1 RP5-1115A15.1 SGOL1 SH2B3 SRR TEX15 TMEM133 ULK3 VEGFB ZNF652 |
Heel T-Score |
1.89 |
36 |
28 |
62.2 |
-0.13 |
4.4e-01 |
ABO ACP2 ATG7 BICC1 C20orf160 CAPZA1 CCDC36 CMIP CTSW CYB5D1 DCAF16 FAM57B GTF2B HEXIM1 INPP5A KAT8 LFNG NCOA1 NELFCD NT5C2 PMS2P5 RHOC RP11-810M2.2 RP4-635E18.7 RP5-1115A15.1 SIPA1 SOX6 STK32C TH1L TMEM133 TNFRSF25 TNFSF12 TUBB1 WNT3 ZNF318 ZNRF3 |
BMI |
2.21 |
40 |
24 |
53.3 |
0.57 |
1.1e-04 |
AC006111.1 AC091133.1 C20orf160 C4orf22 CAST CEP41 CHP1 CISD2 CLCN6 COX5A CTB-31O20.6 CTSW FAM108C1 FAM57B FBF1 HSD17B12 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 MRAS NRBF2 NT5C2 PDE1A PMS2P5 RGS19 RNF34 RP11-296I10.6 RP11-538P18.2 RP5-1115A15.1 RPP25 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 TSPY26P USP37 |
Height |
1.71 |
53 |
43 |
95.6 |
-0.34 |
1.4e-02 |
ABO AC006111.1 AC091133.1 ACE ACP2 ADRB1 ARID3B BICC1 CAPZA1 CENPW CERS5 CHP1 CTSW DBN1 DCAF16 EFR3B FAM57B FES FURIN GOPC GTF2B HEXIM1 HRCT1 LSP1 MGRN1 NCOA1 NT5C2 NTN5 NUCB2 PDLIM4 PIGV PTPN12 RBL2 RHOC RP11-1055B8.4 RP11-538P18.2 RP11-617D20.1 RP11-810M2.2 RP4-635E18.7 RP5-1115A15.1 SH2B3 SLC35F6 SLC4A7 STAG3L1 TMEM133 TMEM170A ULK3 USP37 WDR66 YEATS4 ZNF318 ZNF652 ZNF831 |
Waist Hip Ratio (WHR) |
2.20 |
23 |
14 |
31.1 |
0.61 |
7.6e-04 |
CEP41 CMIP CTSW DBN1 FLJ12825 GTF2B MRAS MYO9B NCOA1 NTN5 OPRL1 PTPN12 RBL2 RGS19 SIK2 SIPA1 SWAP70 TBC1D19 TCEA2 VEGFB WNT3 ZNF318 ZNRF3 |
Systolic Blood Pressure |
13.21 |
124 |
105 |
233.3 |
0.96 |
9.3e-82 |
ABCF3 AC006111.1 AC091133.1 ACE ACP2 ADRB1 ADRB2 AGT AKR1B1 ARID3B ATG7 ATP2B1 BICC1 C10orf118 C1GALT1 C20orf160 C4orf22 CACNB2 CAPZA1 CCDC36 CENPW CERS5 CHP1 CLCN6 CMIP COX5A CSK CTB-31O20.6 CTSW CWF19L2 CYB5D1 DCAF16 EFR3B ENPEP FAM108C1 FBF1 FCF1P2 FCN3 FES FLJ12825 FURIN GMEB2 GOPC GTF2B HDAC7 HEXIM1 HOXA10 HRCT1 IPO11 KB-1107E3.1 KDM2B KLF16 LDB3 LFNG LSP1 MGRN1 MPI MRAS MTHFR MYO9B NCOA1 NDUFAF6 NEIL2 NELFCD NOC3L NPPA NPPA-AS1 NRBF2 NSUN6 NT5C2 NTN5 NUCB2 OPRL1 PDE1A PDXK PHIP PIGV PLCB1 PRDM8 PRKD3 PTPN12 RGS19 RHOC RNF34 RP11-1055B8.4 RP11-296I10.6 RP11-538P18.2 RP11-588K22.2 RP4-635E18.7 RP5-1115A15.1 RPP25 SH2B3 SIK2 SIPA1 SLC2A4 SLC4A7 SOX6 SRR STAG3L1 SWAP70 TBC1D19 TCEA2 TCHP TH1L TMEM133 TMEM170A TNFRSF25 TNFSF12 TNNT3 TUBB1 UBL7 UCKL1AS UFL1 ULK3 VEGFB WDR66 WNT3 ZBTB46 ZC3HC1 ZNF318 ZNF641 ZNF652 ZNF831 ZNRF3 |
Smoking Status |
1.30 |
6 |
0 |
0.0 |
-0.16 |
7.3e-01 |
CTSW FAM108C1 FES RP5-1115A15.1 SRR ZNF652 |
Allergy or Eczema |
2.06 |
13 |
5 |
11.1 |
0.26 |
4.0e-01 |
ABO CHP1 CLCN6 GMEB2 HDAC7 HEXIM1 NRBF2 PDLIM4 RNF34 RP5-1115A15.1 SIK2 SRR ZNF652 |
Cardiovascular Disease |
13.49 |
142 |
117 |
260.0 |
0.99 |
4.0e-134 |
ABCF3 AC006111.1 AC091133.1 ACE ACP2 ADRB1 ADRB2 AGT AKR1B1 ARID3B ATG7 ATP2B1 BICC1 C10orf118 C1GALT1 C20orf160 C4orf22 CACNB2 CAPZA1 CAST CCDC36 CENPW CEP41 CERS5 CHMP1A CHP1 CISD2 CLCN6 CMIP COX5A CSK CTB-31O20.6 CTSW CWF19L2 CYB5D1 DBN1 DCAF16 EFR3B ENPEP EXOC4 FAM108C1 FAM57B FBF1 FCF1P2 FCN3 FES FLJ12825 FURIN GMEB2 GOPC GTF2B HEXIM1 HOXA10 HRCT1 HSD17B12 IPO11 JARID2 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 LDB3 LFNG LSP1 MGRN1 MOBP MPI MRAS MTHFR MYO9B NCOA1 NDUFAF6 NELFCD NOC3L NPPA NPPA-AS1 NRBF2 NSUN6 NT5C2 NTN5 NUCB2 OPRL1 PDE1A PDXK PHIP PIGV PLCB1 PMS2P5 PRDM8 PTPN12 PVRIG RBL2 RGS19 RHOC RNF34 RP11-1055B8.4 RP11-296I10.6 RP11-538P18.2 RP11-588K22.2 RP11-617D20.1 RP11-810M2.2 RP4-635E18.7 RP5-1115A15.1 RPP25 SH2B3 SIK2 SIPA1 SLC2A4 SLC35F6 SLC4A7 SOX6 STAG3L1 SWAP70 TBC1D19 TCEA2 TCHP TDRD1 TEX15 TH1L TMEM133 TMEM170A TNFRSF25 TNFSF12 TNNT3 TSPY26P TUBB1 UBL7 UCKL1AS UFL1 ULK3 USP37 VEGFB WDR66 YEATS4 ZBTB46 ZC3HC1 ZNF318 ZNF641 ZNF652 ZNF831 ZNRF3 |
Hypothyroidism (self reported) |
1.82 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
NTN5 RP5-1115A15.1 SH2B3 |
Respiratory disease |
1.73 |
9 |
3 |
6.7 |
0.58 |
1.0e-01 |
CHP1 FBF1 GMEB2 HDAC7 HEXIM1 PDLIM4 RP5-1115A15.1 SIK2 ZNF652 |
Type 2 Diabetes (T2D) (2018) |
2.12 |
9 |
2 |
4.4 |
0.97 |
1.6e-05 |
ACE CTSW MRAS NDUFAF6 PMS2P5 RBL2 SH2B3 VEGFB ZBTB46 |
Lung FEV1/FVC ratio |
1.84 |
27 |
15 |
33.3 |
-0.36 |
6.2e-02 |
ABO ATG7 ATP2B1 C1GALT1 CACNB2 CENPW CEP41 CTB-31O20.6 CYB5D1 FLJ12825 GOPC HDAC7 INPP5A KB-1107E3.1 NRBF2 NTN5 PDLIM4 PVRIG RP11-810M2.2 RP5-1115A15.1 STK32C TMEM133 TMEM170A TNFRSF25 TSPY26P WNT3 ZNF652 |
Lung FVC |
1.68 |
17 |
11 |
24.4 |
-0.25 |
2.9e-01 |
C1GALT1 CHP1 DCAF16 FLJ12825 GMEB2 HOXA10 HSD17B12 KAT8 NCOA1 NRBF2 OPRL1 PDLIM4 RGS19 RP11-538P18.2 TNFRSF25 WNT3 ZBTB46 |
Neuroticism |
1.15 |
4 |
2 |
4.4 |
-0.46 |
5.4e-01 |
FURIN NT5C2 RP5-1115A15.1 WNT3 |
Chronotype (morning person) |
1.08 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP11-810M2.2 RP5-1115A15.1 |
Hair Pigment |
0.91 |
17 |
10 |
22.2 |
0.25 |
3.0e-01 |
ACP2 ATP2B1 C20orf160 C4orf22 CHMP1A CTSW FES OPRL1 PIGV RGS19 SH2B3 SIPA1 SOX6 TSPY26P WNT3 ZNF831 ZNRF3 |
Tanning |
1.37 |
6 |
3 |
6.7 |
-0.28 |
5.9e-01 |
CHMP1A DBN1 NRBF2 SH2B3 TSPY26P UBL7 |
Hand grip strength (left) |
1.44 |
6 |
2 |
4.4 |
-0.64 |
1.7e-01 |
DCAF16 FAM57B FES HEXIM1 MGRN1 PDLIM4 |
Number of treatments/medications taken |
4.11 |
15 |
6 |
13.3 |
0.94 |
1.6e-07 |
AC091133.1 ACE CHP1 CISD2 DCAF16 FAM108C1 FES RP11-617D20.1 SH2B3 STK32C TMEM133 YEATS4 ZNF652 ZNF831 ZNRF3 |
Sensitivity / hurt feelings |
1.38 |
4 |
3 |
6.7 |
-0.64 |
2.4e-01 |
AC091133.1 FES FURIN WNT3 |
Frequency of depressed mood in last 2 weeks |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP5-1115A15.1 |
Hearing difficulty/problems: Yes |
1.03 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ZNF318 |
Relative age of first facial hair |
1.28 |
5 |
3 |
6.7 |
-0.74 |
1.6e-01 |
ATG7 C4orf22 HEXIM1 SIPA1 WNT3 |
Systolic blood pressure, automated reading |
10.01 |
90 |
58 |
128.9 |
0.98 |
7.1e-66 |
AC006111.1 ACP2 ADRB1 ADRB2 AGT ATG7 ATP2B1 BICC1 C4orf22 CACNB2 CAPZA1 CCDC36 CERS5 CHP1 CLCN6 CMIP COX5A CSK CTB-31O20.6 CTSW CWF19L2 DCAF16 FAM108C1 FAM57B FCF1P2 FES FLJ12825 FURIN GMEB2 GOPC GTF2B HDAC7 HEXIM1 HOXA10 INPP5A IPO11 KLF16 LFNG LSP1 MGRN1 MPI MSRA MTHFR MYO9B NCOA1 NEIL2 NOC3L NPPA NPPA-AS1 NRBF2 NSUN6 NT5C2 NUCB2 OPRL1 PDE1A PHIP PIGV PMS2P5 PRKD3 RGS19 RHOC RP11-296I10.6 RP11-538P18.2 RP11-588K22.2 RP4-635E18.7 RP5-1115A15.1 RPP25 SH2B3 SLC2A4 SLC4A7 SOX6 SRR STAG3L1 SWAP70 TBC1D19 TCEA2 TCHP TH1L TMEM133 TMEM170A TNFSF12 TNNT3 UBL7 UFL1 ULK3 WNT3 ZBTB46 ZNF318 ZNF831 ZNRF3 |
Angina |
2.93 |
5 |
3 |
6.7 |
0.96 |
6.6e-04 |
FES FURIN OPRL1 RGS19 ZNF652 |
Medication: Metformin |
1.75 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CISD2 PMS2P5 |
Diabetes (father) |
1.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC091133.1 |
Pack years adult smoking proportion |
1.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 |
Impedance of leg (right) |
2.30 |
40 |
20 |
44.4 |
-0.03 |
8.7e-01 |
ABCF3 AC091133.1 ATG7 CEP41 CERS5 CTB-31O20.6 CTSW DBN1 FAM108C1 FAM57B FES FLJ12825 FURIN HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA MYO9B NEIL2 NELFCD NOC3L NT5C2 NUCB2 PDE1A PMS2P5 PRKD3 RBL2 RGS19 SLC35F6 SRR STAG3L1 SWAP70 TH1L TMEM133 USP37 WDR66 ZNF641 ZNF652 |
Leg fat-free mass (left) |
1.92 |
27 |
15 |
33.3 |
0.19 |
3.5e-01 |
ABCF3 C10orf118 CENPW CTB-31O20.6 CTSW DBN1 DCAF16 FAM108C1 FAM57B FES FURIN HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SLC35F6 SRR STAG3L1 TDRD1 WDR66 |
Trunk fat percentage |
1.99 |
27 |
11 |
24.4 |
0.67 |
1.5e-04 |
ABO AC091133.1 CHP1 CTB-31O20.6 CTSW FAM108C1 FAM57B FLJ12825 HOXA10 HSD17B12 KAT8 KCNK3 KDM2B MRAS MYO9B NOC3L RNF34 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 SRR STAG3L1 STK32C TEX15 TNFRSF25 TNFSF12 WNT3 |
Hand grip strength (right) |
1.58 |
8 |
3 |
6.7 |
-0.66 |
7.4e-02 |
ABO CAPZA1 DCAF16 HEXIM1 JARID2 PDLIM4 RHOC UCKL1AS |
Townsend deprivation index at recruitment |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KLF16 |
Current tobacco smoking |
1.62 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MSRA |
Maternal smoking around birth |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C20orf160 |
Fed-up feelings |
1.25 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
SH2B3 SLC2A4 TEX15 |
Relative age voice broke |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
WNT3 |
Taking other prescription medications |
2.04 |
4 |
2 |
4.4 |
1.00 |
1.8e-03 |
CISD2 PMS2P5 SH2B3 ZNF652 |
Age when periods started (menarche) |
1.67 |
9 |
4 |
8.9 |
-0.05 |
9.0e-01 |
CCDC36 CTB-31O20.6 CTSW FAM57B HSD17B12 KLF16 NTN5 PMS2P5 STAG3L1 |
Heel bone mineral density (BMD) T-score, automated (left) |
1.67 |
8 |
4 |
8.9 |
-0.21 |
6.2e-01 |
ACP2 CMIP CYB5D1 MSRA NEIL2 RP5-1115A15.1 SIPA1 ZNRF3 |
High blood pressure |
14.82 |
154 |
139 |
308.9 |
1.00 |
1.0e-234 |
ABCF3 ABO AC006111.1 AC091133.1 ACE ACP2 ADRB1 ADRB2 AGT AKR1B1 ARID3B ATG7 ATP2B1 BICC1 C10orf118 C1GALT1 C20orf160 C4orf22 CACNB2 CAPZA1 CAST CCDC36 CENPW CEP41 CERS5 CHMP1A CHP1 CISD2 CLCN6 CMIP COX5A CSK CTB-31O20.6 CTSW CWF19L2 CYB5D1 DBN1 DCAF16 EFR3B ENPEP EXOC4 FAM108C1 FAM57B FBF1 FCF1P2 FCN3 FES FLJ12825 FURIN GMEB2 GOPC GTF2B HDAC7 HEXIM1 HOXA10 HRCT1 HSD17B12 INPP5A IPO11 JARID2 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 LDB3 LFNG LSP1 MGRN1 MOBP MPI MRAS MSRA MTHFR MYO9B NCOA1 NDUFAF6 NEIL2 NELFCD NOC3L NPPA NPPA-AS1 NRBF2 NSUN6 NT5C2 NTN5 NUCB2 OPRL1 OSGIN2 PDE1A PDLIM4 PDXK PHIP PIGV PLCB1 PMS2P5 PRDM8 PRKD3 PTPN12 PVRIG RBL2 RGS19 RHOC RNF34 RP11-1055B8.4 RP11-296I10.6 RP11-538P18.2 RP11-588K22.2 RP11-617D20.1 RP11-810M2.2 RP4-635E18.7 RP5-1115A15.1 RPP25 SGOL1 SH2B3 SIK2 SIPA1 SLC2A4 SLC35F6 SLC4A7 SOX6 SRR STAG3L1 STK32C SWAP70 TBC1D19 TCEA2 TCHP TDRD1 TEX15 TH1L TMEM133 TMEM170A TNFRSF25 TNFSF12 TNNT3 TSPY26P TUBB1 UBL7 UCKL1AS UFL1 ULK3 USP37 VEGFB WDR66 WNT3 YEATS4 ZBTB46 ZC3HC1 ZNF318 ZNF641 ZNF652 ZNF831 ZNRF3 |
Hayfever, allergic rhinitis or eczema |
1.96 |
5 |
5 |
11.1 |
0.57 |
3.1e-01 |
CHP1 PDLIM4 RP5-1115A15.1 SIK2 ZNF652 |
Supplements: Glucosamine |
1.59 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CSK NRBF2 |
Medication: Atenolol |
5.41 |
7 |
2 |
4.4 |
0.99 |
4.3e-06 |
CLCN6 FES FURIN PRKD3 RHOC SH2B3 TMEM133 |
Medication: Levothyroxine sodium |
1.68 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MSRA SH2B3 |
Sitting height |
1.44 |
25 |
14 |
31.1 |
-0.17 |
4.1e-01 |
AC091133.1 ADRB1 C10orf118 C20orf160 CENPW CERS5 CHP1 DCAF16 FCN3 GOPC GTF2B HEXIM1 JARID2 NTN5 PDLIM4 RBL2 RP11-538P18.2 SLC35F6 SLC4A7 WDR66 WNT3 ZNF641 ZNF652 ZNF831 ZNRF3 |
High blood pressure (mother) |
5.55 |
14 |
4 |
8.9 |
0.96 |
4.3e-10 |
AGT CENPW CHMP1A CLCN6 FES FLJ12825 FURIN HOXA10 LSP1 NT5C2 PIGV SLC4A7 TNFRSF25 ZNF831 |
Body mass index (BMI) |
2.35 |
30 |
18 |
40.0 |
0.78 |
2.9e-07 |
AC091133.1 CAST CEP41 COX5A CTB-31O20.6 CTSW DCAF16 FAM108C1 FAM57B HSD17B12 KAT8 KCNK3 KDM2B KLF16 MSRA NEIL2 NRBF2 NT5C2 PDE1A PMS2P5 RP11-296I10.6 RP5-1115A15.1 RPP25 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 USP37 |
Impedance of leg (left) |
2.31 |
37 |
22 |
48.9 |
-0.07 |
6.5e-01 |
ABCF3 AC091133.1 ATG7 CEP41 CERS5 CTB-31O20.6 CTSW DBN1 FAM108C1 FAM57B FES FLJ12825 FURIN HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA MYO9B NEIL2 NELFCD NOC3L NT5C2 NUCB2 PMS2P5 PRKD3 RBL2 RGS19 RP11-296I10.6 SLC35F6 SRR STAG3L1 SWAP70 TMEM133 USP37 ZNF652 |
Leg predicted mass (left) |
1.92 |
27 |
15 |
33.3 |
0.15 |
4.7e-01 |
ABCF3 C10orf118 CENPW CTSW DBN1 DCAF16 FAM108C1 FAM57B FES FURIN HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA MYO9B NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SLC35F6 SRR STAG3L1 TDRD1 WDR66 |
Trunk fat mass |
1.96 |
24 |
9 |
20.0 |
0.65 |
5.7e-04 |
CAST CTB-31O20.6 CTSW FAM108C1 FAM57B HOXA10 HSD17B12 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 MRAS NT5C2 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 |
Waist circumference |
2.26 |
26 |
12 |
26.7 |
0.70 |
6.3e-05 |
CMIP COX5A CTB-31O20.6 CTSW EFR3B EXOC4 FAM108C1 FAM57B HSD17B12 KAT8 KB-1107E3.1 KCNK3 KLF16 MPI NRBF2 PHIP RP11-296I10.6 RP11-810M2.2 RPP25 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 UBL7 |
Number of incorrect matches in round |
1.41 |
4 |
1 |
2.2 |
-1.00 |
2.6e-06 |
FAM57B FES FURIN KAT8 |
Past tobacco smoking |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SH2B3 |
Alcohol usually taken with meals |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Nervous feelings |
1.32 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
KAT8 MSRA NT5C2 |
Frequency of tenseness / restlessness in last 2 weeks |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NT5C2 |
Hearing difficulty/problems with background noise |
1.52 |
4 |
2 |
4.4 |
-0.99 |
8.3e-03 |
CSK UBL7 ULK3 ZNF318 |
Hair/balding pattern: Pattern 2 |
1.51 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C4orf22 PRDM8 |
Had menopause |
1.04 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CHP1 |
Forced vital capacity (FVC) |
1.71 |
11 |
6 |
13.3 |
-0.36 |
2.8e-01 |
CAPZA1 CENPW DCAF16 GMEB2 KAT8 NCOA1 RBL2 RHOC RP11-538P18.2 WDR66 WNT3 |
Heel bone mineral density (BMD) T-score, automated (right) |
1.65 |
7 |
5 |
11.1 |
-0.17 |
7.2e-01 |
ACP2 CYB5D1 MSRA NEIL2 RP5-1115A15.1 SIPA1 ZNRF3 |
Qualifications: None of the above |
1.35 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHIP RBL2 |
Mouth/teeth dental problems |
1.41 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NTN5 PMS2P5 |
Heart attack |
2.53 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES ZC3HC1 ZNF652 |
Allergy |
2.22 |
10 |
6 |
13.3 |
-0.19 |
6.1e-01 |
ABO CHP1 FES GMEB2 HDAC7 HEXIM1 PDLIM4 RP5-1115A15.1 SIK2 ZNF652 |
Diabetes (self-reported) |
1.94 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PMS2P5 RBL2 ZBTB46 |
Medication: Ramipril |
4.77 |
8 |
2 |
4.4 |
0.98 |
2.9e-05 |
CISD2 CMIP CSK FES GOPC LSP1 TMEM133 ZC3HC1 |
Medication: Simvastatin |
4.22 |
10 |
4 |
8.9 |
0.76 |
1.5e-03 |
ABO DCAF16 FES NTN5 OPRL1 PIGV RGS19 VEGFB YEATS4 ZNF831 |
Fluid intelligence score |
1.17 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
DCAF16 RBL2 |
Illnesses of siblings |
3.88 |
7 |
2 |
4.4 |
-0.98 |
1.4e-06 |
CLCN6 FES KAT8 NRBF2 RBL2 SH2B3 TMEM133 |
Neuroticism score |
1.18 |
4 |
3 |
6.7 |
-0.99 |
1.1e-02 |
MSRA NEIL2 RP5-1115A15.1 WNT3 |
Weight |
2.00 |
30 |
16 |
35.6 |
0.44 |
1.5e-02 |
C10orf118 CAST CTB-31O20.6 CTSW DCAF16 EFR3B EXOC4 FAM108C1 FAM57B HSD17B12 KAT8 KB-1107E3.1 KCNK3 KLF16 MRAS MSRA NEIL2 NT5C2 PDE1A PDLIM4 RBL2 RP11-296I10.6 RP11-810M2.2 RPP25 SH2B3 SRR STAG3L1 STK32C TDRD1 WDR66 |
Impedance of arm (right) |
2.05 |
31 |
14 |
31.1 |
-0.45 |
1.1e-02 |
ABO ARID3B CCDC36 CERS5 CISD2 CMIP CTB-31O20.6 CTSW FAM57B FLJ12825 HEXIM1 HOXA10 HSD17B12 KAT8 KLF16 LSP1 MSRA MYO9B NEIL2 NOC3L NRBF2 NUCB2 PDE1A RGS19 SLC4A7 STAG3L1 TNFSF12 TSPY26P UCKL1AS ZNF641 ZNF652 |
Arm fat percentage (right) |
2.20 |
30 |
17 |
37.8 |
0.66 |
7.8e-05 |
ABO AC091133.1 CHP1 COX5A CTB-31O20.6 CTSW DCAF16 FAM108C1 FAM57B FBF1 HOXA10 HSD17B12 KAT8 KCNK3 KDM2B KLF16 MSRA NT5C2 PMS2P5 RNF34 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 SLC2A4 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 |
Trunk fat-free mass |
1.86 |
25 |
18 |
40.0 |
0.01 |
9.5e-01 |
ABO C10orf118 CENPW DBN1 DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 JARID2 KAT8 KCNK3 KLF16 MYO9B NCOA1 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 SLC4A7 TMEM133 WDR66 |
Hip circumference |
2.14 |
29 |
12 |
26.7 |
0.17 |
3.6e-01 |
CAST CLCN6 CTB-31O20.6 FAM108C1 FAM57B FBF1 HSD17B12 KAT8 KB-1107E3.1 KCNK3 KLF16 MRAS MSRA NPPA NPPA-AS1 NT5C2 PDE1A PHIP PMS2P5 RBL2 RGS19 RP11-296I10.6 RP11-810M2.2 SH2B3 SRR STAG3L1 STK32C VEGFB WDR66 |
Alcohol intake versus 10 years previously |
1.15 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FAM57B NTN5 |
Father's age at death |
2.27 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ABO FES SH2B3 |
Worrier / anxious feelings |
1.51 |
4 |
1 |
2.2 |
-0.59 |
4.1e-01 |
KAT8 MSRA NEIL2 NT5C2 |
Frequency of tiredness / lethargy in last 2 weeks |
1.37 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
AC091133.1 CCDC36 RP5-1115A15.1 |
Hair/balding pattern: Pattern 3 |
1.76 |
4 |
2 |
4.4 |
0.71 |
2.9e-01 |
C4orf22 HEXIM1 PRDM8 WNT3 |
Forced expiratory volume in 1-second (FEV1) |
1.77 |
13 |
3 |
6.7 |
-0.30 |
3.1e-01 |
ABO DCAF16 GOPC KAT8 MSRA NCOA1 NRBF2 PDLIM4 RHOC RP11-538P18.2 TMEM133 TSPY26P WNT3 |
Pulse rate |
1.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 |
Qualifications: A levels/AS levels or equivalent |
1.25 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 STAG3L1 |
Serious illness, injury or assault of a close relative in last 2 years |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NTN5 |
Mouth/teeth dental problems: Dentures |
1.22 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
NTN5 RP11-1055B8.4 |
Asthma |
1.89 |
5 |
4 |
8.9 |
0.63 |
2.6e-01 |
HDAC7 PDLIM4 RP5-1115A15.1 SIK2 ZNF652 |
Medication: Cholesterol lowering |
4.20 |
13 |
5 |
11.1 |
0.85 |
1.6e-05 |
ABO CHP1 CLCN6 FES NTN5 OPRL1 PIGV PVRIG RGS19 TMEM133 TNFRSF25 YEATS4 ZNF831 |
Depression (self-reported) |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP5-1115A15.1 |
Illnesses of mother |
3.65 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.69 |
9 |
5 |
11.1 |
-0.24 |
5.3e-01 |
ABO DCAF16 KAT8 NCOA1 NRBF2 PDLIM4 RP11-538P18.2 TMEM133 WNT3 |
Pulse wave Arterial Stiffness index |
1.84 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
VEGFB |
Impedance of arm (left) |
2.09 |
31 |
17 |
37.8 |
-0.39 |
3.2e-02 |
ABO ARID3B CCDC36 CERS5 CISD2 CMIP CTSW FAM108C1 FAM57B FLJ12825 HEXIM1 HOXA10 HSD17B12 KAT8 LSP1 MSRA MYO9B NEIL2 NOC3L NRBF2 PDE1A PRKD3 RGS19 SH2B3 SLC4A7 STAG3L1 TNFSF12 TSPY26P UCKL1AS ZNF641 ZNF652 |
Arm fat mass (right) |
2.19 |
28 |
13 |
28.9 |
0.69 |
4.1e-05 |
AC091133.1 CAST COX5A CTB-31O20.6 CTSW EFR3B FAM108C1 FAM57B HOXA10 HSD17B12 KAT8 KCNK3 KDM2B KLF16 MSRA NT5C2 PDE1A PMS2P5 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 |
Trunk predicted mass |
1.86 |
24 |
17 |
37.8 |
0.05 |
8.3e-01 |
ABO C10orf118 CENPW DBN1 DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 JARID2 KAT8 KCNK3 KLF16 MYO9B NCOA1 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 SLC4A7 WDR66 |
Standing height |
1.66 |
42 |
25 |
55.6 |
-0.29 |
6.3e-02 |
AC006111.1 AC091133.1 ACP2 ADRB1 C10orf118 CAPZA1 CENPW CERS5 CHP1 DBN1 DCAF16 EFR3B FAM57B GOPC GTF2B HEXIM1 LSP1 MGRN1 MSRA NCOA1 NUCB2 PDLIM4 PIGV PTPN12 RBL2 RHOC RP11-1055B8.4 RP11-538P18.2 RP11-617D20.1 RP11-810M2.2 RP4-635E18.7 RP5-1115A15.1 SH2B3 SLC35F6 SLC4A7 TMEM170A ULK3 USP37 WDR66 ZNF318 ZNF652 ZNF831 |
Tense / 'highly strung' |
1.10 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
KAT8 NT5C2 RP5-1115A15.1 |
Hair/balding pattern: Pattern 4 |
2.04 |
8 |
6 |
13.3 |
0.49 |
2.2e-01 |
C4orf22 CENPW CERS5 HEXIM1 PRDM8 RP5-1115A15.1 SRR WNT3 |
Birth weight of first child |
3.32 |
15 |
4 |
8.9 |
-0.98 |
1.9e-13 |
CLCN6 COX5A CSK DCAF16 FES FURIN GTF2B MTHFR NPPA-AS1 OPRL1 RGS19 RPP25 SH2B3 STAG3L1 TMEM170A |
Peak expiratory flow (PEF) |
1.71 |
8 |
4 |
8.9 |
-0.61 |
1.1e-01 |
ABO C1GALT1 DCAF16 MSRA NTN5 SLC2A4 TMEM170A WNT3 |
Pulse wave reflection index |
1.30 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FLJ12825 INPP5A |
Blood clot in the leg (DVT) |
2.96 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO |
Medication: Paracetamol |
1.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UFL1 |
Headache pain in last month |
1.51 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
TMEM170A UFL1 WNT3 |
Medication for cholesterol, blood pressure or diabetes |
8.17 |
37 |
14 |
31.1 |
-0.98 |
5.4e-33 |
ACE ATP2B1 C1GALT1 C4orf22 CHP1 CISD2 CLCN6 CSK CTSW FAM108C1 FCF1P2 FES FURIN JARID2 LFNG MTHFR OPRL1 OSGIN2 PDXK PLCB1 PVRIG RGS19 RHOC RP11-296I10.6 RP11-588K22.2 SH2B3 SIK2 SLC4A7 TH1L TMEM133 TNFRSF25 TSPY26P ULK3 YEATS4 ZBTB46 ZNF652 ZNF831 |
Gout (self-reported) |
1.58 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SH2B3 SIPA1 |
Hypothyroidism/myxoedema (self-reported) |
1.65 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
MSRA RP5-1115A15.1 SH2B3 |
Medication: Amlodipine |
6.19 |
19 |
9 |
20.0 |
0.95 |
1.8e-12 |
CAPZA1 CLCN6 FAM108C1 FES KCNK3 KDM2B LSP1 MTHFR NPPA-AS1 OSGIN2 RHOC RNF34 RP11-617D20.1 RP4-635E18.7 SLC35F6 TMEM133 TNFSF12 TNNT3 ZNF318 |
Medication: Ventolin 100micrograms inhaler |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZNF652 |
Birth weight |
2.73 |
13 |
9 |
20.0 |
-0.58 |
2.9e-02 |
ADRB1 DBN1 DCAF16 FES FURIN NTN5 SH2B3 SIK2 SLC2A4 SRR TNNT3 UCKL1AS ZNRF3 |
High blood pressure (siblings) |
4.96 |
9 |
4 |
8.9 |
0.98 |
2.1e-08 |
ACP2 CLCN6 FES KAT8 NPPA NRBF2 RHOC SH2B3 TMEM133 |
Forced vital capacity (FVC), Best measure |
1.57 |
11 |
5 |
11.1 |
-0.44 |
1.7e-01 |
ACP2 CENPW DBN1 DCAF16 GMEB2 KAT8 NCOA1 RBL2 RHOC RP11-538P18.2 WNT3 |
Body fat percentage |
2.11 |
30 |
11 |
24.4 |
0.61 |
3.9e-04 |
ABO AC091133.1 CAST CHP1 COX5A CTB-31O20.6 CTSW DCAF16 FAM108C1 FAM57B FLJ12825 HOXA10 HSD17B12 KAT8 KCNK3 KDM2B MRAS MYO9B NOC3L PMS2P5 RNF34 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 SRR STAG3L1 STK32C TEX15 TNFRSF25 |
Leg fat percentage (right) |
2.21 |
23 |
12 |
26.7 |
0.82 |
1.4e-06 |
CHP1 COX5A CTB-31O20.6 CTSW DCAF16 FAM108C1 FAM57B GTF2B HSD17B12 KAT8 KCNK3 KDM2B MOBP MSRA NOC3L RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 STAG3L1 STK32C TEX15 TNFRSF25 |
Arm fat-free mass (right) |
1.88 |
23 |
13 |
28.9 |
0.17 |
4.3e-01 |
ABO C10orf118 CENPW CTSW DBN1 DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MYO9B NEIL2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 STAG3L1 WDR66 |
Comparative body size at age 10 |
1.65 |
11 |
6 |
13.3 |
0.34 |
3.1e-01 |
ATG7 CERS5 EFR3B FAM57B FCF1P2 KAT8 MSRA NTN5 SIPA1 SRR ZNF652 |
Worry too long after embarrassment |
1.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MSRA |
Seen a psychiatrist for nerves, anxiety, tension or depression |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADRB1 |
Wheeze or whistling in the chest in last year |
1.67 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
GMEB2 SIK2 ZNF652 |
Qualifications: College or University degree |
1.12 |
8 |
2 |
4.4 |
-0.75 |
3.1e-02 |
DCAF16 FAM57B GTF2B RBL2 STAG3L1 TEX15 TNFRSF25 WNT3 |
Medication for pain relief, constipation, heartburn |
1.95 |
6 |
2 |
4.4 |
-0.98 |
5.4e-04 |
ACE C20orf160 FAM108C1 STK32C UFL1 YEATS4 |
Neck or shoulder pain in last month |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP5-1115A15.1 |
Medication: Blood pressure |
10.31 |
68 |
28 |
62.2 |
0.99 |
1.3e-63 |
AC091133.1 ACE ACP2 ADRB1 ATP2B1 BICC1 C1GALT1 C20orf160 C4orf22 CAPZA1 CEP41 CHMP1A CISD2 CLCN6 CMIP CSK CTSW CWF19L2 CYB5D1 DCAF16 EFR3B FAM108C1 FAM57B FCF1P2 FES FURIN HOXA10 JARID2 KDM2B KLF16 LDB3 LFNG LSP1 MOBP MSRA MTHFR NELFCD NOC3L NPPA NPPA-AS1 OSGIN2 PDXK PLCB1 PRDM8 PVRIG RGS19 RHOC RNF34 RP11-810M2.2 RP4-635E18.7 SH2B3 SIK2 SIPA1 SLC2A4 SLC4A7 SOX6 STAG3L1 TH1L TMEM133 TNNT3 TSPY26P ULK3 WDR66 ZBTB46 ZC3HC1 ZNF318 ZNF652 ZNF831 |
Angina (self-reported) |
2.91 |
5 |
1 |
2.2 |
0.97 |
3.9e-04 |
FES FURIN OPRL1 RGS19 ZNF652 |
Migraine (self-reported) |
1.28 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
UFL1 |
Medication: Allopurinol |
1.58 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CYB5D1 SH2B3 WDR66 |
Medication: Seretide 50 evohaler |
1.36 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
PDLIM4 ZNF652 |
Mean time to correctly identify matches |
1.15 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP11-810M2.2 SH2B3 |
Whole body fat mass |
2.04 |
28 |
14 |
31.1 |
0.65 |
2.0e-04 |
AC091133.1 CAST COX5A CTB-31O20.6 CTSW FAM108C1 FAM57B HOXA10 HSD17B12 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 MRAS MSRA NT5C2 PMS2P5 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 |
Leg fat mass (right) |
2.14 |
25 |
12 |
26.7 |
0.85 |
1.0e-07 |
AC091133.1 CAST CTB-31O20.6 CTSW FAM108C1 FAM57B HSD17B12 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 MOBP MRAS MSRA PMS2P5 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 STAG3L1 STK32C TEX15 TNFRSF25 TSPY26P |
Arm predicted mass (right) |
1.87 |
24 |
12 |
26.7 |
0.20 |
3.4e-01 |
ABO C10orf118 CENPW CMIP DBN1 DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MYO9B NEIL2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 STAG3L1 TSPY26P WDR66 |
Pulse rate, automated reading |
1.32 |
6 |
2 |
4.4 |
-0.07 |
8.9e-01 |
ABO ACP2 CCDC36 PVRIG RBL2 SIK2 |
Alcohol intake frequency. |
1.60 |
7 |
3 |
6.7 |
0.69 |
8.7e-02 |
ARID3B FAM57B KAT8 NTN5 PMS2P5 TEX15 ZNF318 |
Comparative height size at age 10 |
1.57 |
19 |
10 |
22.2 |
-0.21 |
3.8e-01 |
CENPW DBN1 DCAF16 FAM108C1 FAM57B FES GTF2B NCOA1 NTN5 NUCB2 PDLIM4 PIGV RBL2 RP11-617D20.1 RP11-810M2.2 RP4-635E18.7 RP5-1115A15.1 SH2B3 WDR66 |
Number of full sisters |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NRBF2 |
Suffer from 'nerves' |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP5-1115A15.1 |
Overall health rating |
2.15 |
11 |
5 |
11.1 |
0.99 |
1.3e-09 |
AC091133.1 CTSW DCAF16 HEXIM1 KAT8 MSRA PMS2P5 RBL2 TEX15 TSPY26P ZNF652 |
Had major operations |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZNF652 |
Medication: Aspirin |
3.97 |
6 |
1 |
2.2 |
0.95 |
1.1e-04 |
AC091133.1 FES GOPC OPRL1 RGS19 SIK2 |
Knee pain experienced in last month |
1.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ARID3B |
Gastro-oesophageal reflux (gord) / gastric reflux (Self-reported) |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KDM2B |
Illnesses of father: Heart disease |
2.55 |
3 |
1 |
2.2 |
0.74 |
2.6e-01 |
ABO FES RGS19 |
Smoking status: Previous |
1.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SH2B3 |
Forced expiratory volume in 1-second (FEV1), predicted |
1.31 |
4 |
2 |
4.4 |
-0.95 |
4.5e-02 |
DCAF16 HEXIM1 MGRN1 PDLIM4 |
Whole body fat-free mass |
1.90 |
23 |
17 |
37.8 |
0.08 |
7.3e-01 |
C10orf118 CENPW DBN1 DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MYO9B NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 SLC4A7 STAG3L1 WDR66 |
Leg fat-free mass (right) |
1.95 |
28 |
16 |
35.6 |
0.07 |
7.1e-01 |
ABCF3 C10orf118 CENPW CTSW DBN1 DCAF16 FAM108C1 FAM57B FES FURIN HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA MYO9B NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 SRR STAG3L1 TDRD1 WDR66 |
Arm fat percentage (left) |
2.19 |
27 |
18 |
40.0 |
0.70 |
4.5e-05 |
ABO AC091133.1 CHP1 COX5A CTB-31O20.6 CTSW DCAF16 FAM108C1 FAM57B FBF1 HOXA10 HSD17B12 KAT8 KCNK3 KDM2B KLF16 MSRA PMS2P5 RNF34 RP11-296I10.6 RP5-1115A15.1 SLC2A4 SRR STAG3L1 STK32C TEX15 TNFRSF25 |
Average weekly red wine intake |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MPI |
Mood swings |
1.24 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACP2 OSGIN2 WNT3 |
Loneliness, isolation |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP5-1115A15.1 |
Long-standing illness, disability or infirmity |
1.88 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CHP1 PMS2P5 ZNF652 |
Ever had bowel cancer screening |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SIK2 |
Diabetes diagnosed by doctor |
2.19 |
5 |
2 |
4.4 |
1.00 |
1.6e-04 |
CTSW MRAS PMS2P5 RBL2 ZBTB46 |
Mouth/teeth dental problems: Mouth ulcers |
1.41 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
OSGIN2 |
Medication for cholesterol |
6.77 |
26 |
8 |
17.8 |
-0.97 |
1.4e-16 |
ATG7 C4orf22 CAPZA1 CENPW CHMP1A CISD2 CMIP FES HOXA10 JARID2 KAT8 LSP1 MGRN1 NTN5 PIGV PLCB1 PRKD3 RBL2 RGS19 RHOC SH2B3 TMEM133 VEGFB ZBTB46 ZNF831 ZNRF3 |
Back pain experienced in last month |
1.60 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
WDR66 |
Mineral and other dietary supplements |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NRBF2 |
Breast cancer (self-reported) |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC4A7 |
Asthma (self-reported) |
1.84 |
6 |
4 |
8.9 |
0.43 |
4.0e-01 |
FBF1 HDAC7 PDLIM4 RP5-1115A15.1 SIK2 ZNF652 |
Osteoarthritis (self-reported) |
1.64 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
COX5A RPP25 |
Medication: Aspirin |
4.14 |
5 |
1 |
2.2 |
0.93 |
6.7e-04 |
FES OPRL1 RGS19 SIK2 VEGFB |
Illnesses of father: None of the above (group 1) |
2.62 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES SH2B3 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.68 |
5 |
3 |
6.7 |
-0.22 |
7.2e-01 |
KAT8 NRBF2 RP11-538P18.2 TMEM170A WNT3 |
Whole body water mass |
1.91 |
23 |
17 |
37.8 |
0.07 |
7.4e-01 |
C10orf118 CENPW DBN1 DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA MYO9B NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 STAG3L1 WDR66 |
Leg predicted mass (right) |
1.94 |
27 |
16 |
35.6 |
0.05 |
8.1e-01 |
ABCF3 C10orf118 CENPW DBN1 DCAF16 FAM108C1 FAM57B FES FURIN HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA MYO9B NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 SRR STAG3L1 TDRD1 WDR66 |
Arm fat mass (left) |
2.15 |
29 |
12 |
26.7 |
0.61 |
4.5e-04 |
AC091133.1 CAST COX5A CTB-31O20.6 CTSW EFR3B FAM108C1 FAM57B FBF1 HOXA10 HSD17B12 KAT8 KCNK3 KDM2B KLF16 MRAS MSRA NT5C2 PMS2P5 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 SRR STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 |
Number of self-reported non-cancer illnesses |
4.96 |
16 |
6 |
13.3 |
0.97 |
1.4e-12 |
CISD2 CLCN6 CYB5D1 GMEB2 HDAC7 MYO9B NTN5 OPRL1 PDLIM4 PMS2P5 RGS19 SH2B3 ZNF318 ZNF652 ZNF831 ZNRF3 |
Miserableness |
1.15 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACP2 RP5-1115A15.1 WNT3 |
Eye problems/disorders: Glaucoma |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TEX15 |
Medication: Blood pressure |
11.08 |
89 |
39 |
86.7 |
0.99 |
9.7e-76 |
ACE ACP2 ADRB1 AGT AKR1B1 ARID3B ATG7 ATP2B1 C1GALT1 C4orf22 CACNB2 CAPZA1 CENPW CERS5 CHMP1A CHP1 CISD2 CLCN6 CMIP COX5A CSK CTSW CWF19L2 CYB5D1 FAM108C1 FCF1P2 FES FLJ12825 FURIN GMEB2 GTF2B HEXIM1 HOXA10 HRCT1 KAT8 KB-1107E3.1 KCNK3 KDM2B LFNG LSP1 MGRN1 MPI MRAS MSRA MTHFR MYO9B NCOA1 NEIL2 NPPA NRBF2 NSUN6 NT5C2 NTN5 OPRL1 PDLIM4 PDXK PIGV PLCB1 PRKD3 PTPN12 RGS19 RHOC RNF34 RP11-1055B8.4 RP11-588K22.2 RP11-810M2.2 RP4-635E18.7 RPP25 SH2B3 SIK2 SIPA1 SLC2A4 SLC35F6 SLC4A7 TBC1D19 TDRD1 TEX15 TMEM133 TNFSF12 TNNT3 UBL7 UCKL1AS ULK3 VEGFB WNT3 ZBTB46 ZNF318 ZNF831 ZNRF3 |
Supplements: Fish oil (including cod liver oil) |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
HEXIM1 |
High cholesterol (Self-reported) |
3.74 |
10 |
7 |
15.6 |
0.61 |
2.0e-02 |
ABO CLCN6 DCAF16 FBF1 NTN5 OPRL1 PIGV RGS19 TMEM133 VEGFB |
Medication: Bendroflumethiazide |
7.33 |
33 |
11 |
24.4 |
0.97 |
5.1e-22 |
ABCF3 ACP2 ADRB1 AGT ATP2B1 CACNB2 CAPZA1 CHMP1A CLCN6 CSK FAM108C1 FAM57B FES HOXA10 KAT8 LSP1 MGRN1 MYO9B NEIL2 NRBF2 NTN5 PDLIM4 PIGV PLCB1 RHOC SH2B3 SLC35F6 SLC4A7 TEX15 TMEM133 TNFSF12 USP37 ZNF831 |
Medication: Paracetamol |
1.72 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
UFL1 |
Medication: Lisinopril |
4.55 |
6 |
0 |
0.0 |
0.98 |
5.5e-04 |
ACP2 CSK FCF1P2 LSP1 NRBF2 ZNF831 |
Medication: Atorvastatin |
2.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ABO |
Illnesses of father: High blood pressure |
4.31 |
6 |
1 |
2.2 |
0.99 |
1.0e-05 |
ACE C4orf22 CHMP1A FES NCOA1 PLCB1 |
Ever smoked |
1.28 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
SH2B3 SRR |
Basal metabolic rate |
1.91 |
23 |
17 |
37.8 |
0.18 |
4.0e-01 |
C10orf118 CENPW CTSW DBN1 DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 STAG3L1 WDR66 |
Leg fat percentage (left) |
2.23 |
23 |
10 |
22.2 |
0.82 |
1.7e-06 |
CHP1 COX5A CTB-31O20.6 CTSW DCAF16 FAM108C1 FAM57B GTF2B HSD17B12 KAT8 KCNK3 KDM2B MOBP MSRA PMS2P5 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 STAG3L1 STK32C TEX15 TNFRSF25 |
Arm fat-free mass (left) |
1.87 |
26 |
13 |
28.9 |
0.31 |
1.3e-01 |
ABO C10orf118 CENPW CMIP CTSW DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA NEIL2 NT5C2 PDE1A PDLIM4 RBL2 RP11-810M2.2 SH2B3 SLC35F6 STAG3L1 TSPY26P WDR66 |
Irritability |
1.28 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
CCDC36 MSRA NEIL2 |
Risk taking |
1.25 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
KCNK3 STK32C |
Diastolic blood pressure, automated reading |
9.02 |
84 |
53 |
117.8 |
0.97 |
9.8e-60 |
ABO AC006111.1 AC091133.1 ACE ACP2 ADRB1 AGT ATP2B1 C10orf118 C1GALT1 C20orf160 C4orf22 CACNB2 CAPZA1 CENPW CEP41 CERS5 CHP1 CLCN6 CMIP COX5A CSK CTB-31O20.6 CTSW CWF19L2 CYB5D1 DCAF16 ENPEP FAM108C1 FCF1P2 FES FURIN GMEB2 HDAC7 HEXIM1 HOXA10 HRCT1 IPO11 KAT8 LFNG LSP1 MPI MSRA MTHFR MYO9B NCOA1 NDUFAF6 NEIL2 NELFCD NOC3L NPPA NPPA-AS1 NRBF2 NSUN6 NT5C2 PDLIM4 PHIP PIGV PMS2P5 PVRIG RGS19 RHOC RP11-296I10.6 RP11-538P18.2 RP5-1115A15.1 RPP25 SH2B3 SIPA1 SLC2A4 SRR STAG3L1 SWAP70 TBC1D19 TCEA2 TCHP TH1L TMEM133 TNFSF12 TUBB1 UBL7 ULK3 ZC3HC1 ZNF652 ZNF831 |
Myopia |
1.21 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CAPZA1 |
Vascular/heart problems diagnosed by doctor |
14.42 |
153 |
114 |
253.3 |
-1.00 |
1.6e-176 |
ABCF3 ABO AC006111.1 AC091133.1 ACE ACP2 ADRB1 ADRB2 AGT AKR1B1 ARID3B ATG7 ATP2B1 BICC1 C10orf118 C1GALT1 C20orf160 C4orf22 CACNB2 CAPZA1 CAST CCDC36 CENPW CEP41 CERS5 CHMP1A CHP1 CISD2 CLCN6 CMIP COX5A CSK CTB-31O20.6 CTSW CWF19L2 CYB5D1 DCAF16 EFR3B ENPEP EXOC4 FAM108C1 FAM57B FBF1 FCF1P2 FCN3 FES FLJ12825 FURIN GMEB2 GOPC GTF2B HDAC7 HEXIM1 HOXA10 HRCT1 HSD17B12 INPP5A IPO11 JARID2 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 LDB3 LFNG LSP1 MGRN1 MOBP MPI MRAS MSRA MTHFR MYO9B NCOA1 NDUFAF6 NEIL2 NELFCD NOC3L NPPA NPPA-AS1 NRBF2 NSUN6 NT5C2 NTN5 NUCB2 OPRL1 OSGIN2 PDE1A PDLIM4 PDXK PHIP PIGV PLCB1 PMS2P5 PRDM8 PRKD3 PTPN12 PVRIG RBL2 RGS19 RHOC RNF34 RP11-1055B8.4 RP11-296I10.6 RP11-538P18.2 RP11-588K22.2 RP11-617D20.1 RP11-810M2.2 RP4-635E18.7 RP5-1115A15.1 RPP25 SGOL1 SH2B3 SIK2 SIPA1 SLC2A4 SLC35F6 SLC4A7 SOX6 SRR STAG3L1 STK32C SWAP70 TBC1D19 TCEA2 TCHP TDRD1 TEX15 TH1L TMEM133 TMEM170A TNFRSF25 TNFSF12 TNNT3 TSPY26P TUBB1 UBL7 UCKL1AS UFL1 ULK3 USP37 VEGFB WDR66 WNT3 YEATS4 ZBTB46 ZC3HC1 ZNF318 ZNF641 ZNF652 ZNF831 ZNRF3 |
Cholesterol lowering medication |
3.38 |
8 |
6 |
13.3 |
0.73 |
6.6e-03 |
ABO DCAF16 NTN5 OPRL1 PIGV RGS19 RNF34 VEGFB |
Pain experienced in last month |
1.54 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
KAT8 UFL1 |
Heart attack/myocardial infarction (self-reported) |
2.52 |
4 |
1 |
2.2 |
0.97 |
6.9e-03 |
FES SH2B3 ZC3HC1 ZNF652 |
Deep venous thrombosis (DVT) (self-reported) |
2.95 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ABO |
Heart disease (siblings) |
1.87 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES PVRIG |
Pack years of smoking |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2P5 |
Impedance of whole body |
2.23 |
39 |
20 |
44.4 |
-0.35 |
2.7e-02 |
ABCF3 ABO ATG7 CCDC36 CENPW CEP41 CERS5 CISD2 CTB-31O20.6 CTSW DBN1 FAM108C1 FAM57B FLJ12825 HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 LSP1 MSRA MYO9B NEIL2 NOC3L NT5C2 NUCB2 PDE1A PMS2P5 PRKD3 RGS19 RP11-296I10.6 SLC4A7 SRR STAG3L1 SWAP70 TNFSF12 USP37 ZNF641 ZNF652 |
Leg fat mass (left) |
2.15 |
26 |
14 |
31.1 |
0.83 |
1.2e-07 |
AC091133.1 CAST COX5A CTB-31O20.6 CTSW FAM108C1 FAM57B HSD17B12 KAT8 KB-1107E3.1 KCNK3 KDM2B KLF16 MSRA PDE1A PMS2P5 RP11-296I10.6 RP11-810M2.2 RP5-1115A15.1 RPP25 STAG3L1 STK32C TDRD1 TEX15 TNFRSF25 TSPY26P |
Arm predicted mass (left) |
1.90 |
25 |
13 |
28.9 |
0.30 |
1.5e-01 |
ABO C10orf118 CENPW CMIP CTSW DCAF16 EFR3B FAM108C1 FAM57B HEXIM1 HSD17B12 KAT8 KCNK3 KLF16 MSRA NCOA1 NEIL2 NT5C2 PDE1A PDLIM4 RBL2 SH2B3 SLC35F6 STAG3L1 WDR66 |